The study supported by Eris Lifesciences and co-authored by 16 doctors between 2020- 2021, was conducted in partnership with over 1900 physicians and had a sample size of 5080 patients with mean age of 48 years, from across 27 states in India
India Diabetes Study (I.D.S.) revealed that over 55 per cent of newly diagnosed1 Type 2 Diabetes Mellitus (T2DM) patients in India have low HDL-C (High Density Lipid – Cholesterol) values, indicating that they are at higher risk of developing some form of cardiovascular disease in their lifetime. The study also suggested that 42 per cent of all T2DM patients are at a high risk of hypertension. Mean BMI of the patients was recorded to be 27.2 – classified as overweight as per the Indian Consensus Group guidelines.
The study supported by Eris Lifesciences and co-authored by 16 doctors between 2020- 2021, was conducted in partnership with over 1900 physicians and had a sample size of 5080 patients with mean age of 48 years, from across 27 states in India. It has been published in the Public Library of Science (PLOS) journal.
Following the recent recommendations from the LAI and QRISK3 score2, the study aimed at investigating the extent of cardiovascular disease (CVD) risk in newly diagnosed T2DM patients in India. It also highlighted some ways to manage dyslipidaemia – high cholesterol (fats) – in newly diagnosed Type 2 diabetes patients.
Other key findings from this study, with respect to newly diagnosed type 2 diabetes mellitus patients include:
- 92.5 per cent and 83.5 per cent of the total patients are not on any cholesterol lowering and anti-hypertension treatment
- Low HDL-C value was the most frequent major risk (55.6 per cent)
- 82.5 per cent patients appeared to have at least one cholesterol abnormality
- 37.3 per cent patients were hypertensive and younger than 65 years of age
- According to the QRISK3 calculation the obese patients in the current population had 17.1 per cent risk of CVD as compared to 14.8 per cent for those with lower BMI
- 11.2 per cent patients had Target Organ Damage – a chronic kidney disease in the 3b or higher stage